Follow The Filings

TEM Tempus AI Inc.

Information Technology, filed as TEMPUS AI INC (CL A), Equity As of 2026 Q2 among managers we track Quote on Google Finance, opens in a new tab

Bought by 1 manager in 2026 Q2, sold by 1

  • 5 Owners
  • Max 3.8%
  • $663M
  • 1 add 1 reduce 2 small

In 2026 Q2 David Witzke added to Tempus AI, while Samantha McLemore trimmed.

Who owns this now

Largest portfolio weights among holders, up to 3.8% (Cathie Wood, Ark Investment Management). Not free-float ownership.

  1. Cathie Wood Add 3.8%
  2. David Witzke Add 0.97%
  3. Samantha Mclemore Reduce 0.76%
  4. Ron Baron Add 0.08%
  5. Duan Yongping 0.01%

Who owns TEM

Sorted by value, long equity only, as of 2026 Q2.

History
Cathie Wood, Ark Investment Management 3.8%, was 3.4% Small add +4.3% 10,022,634 $581M History
Ron Baron, Bamco Inc. (Baron Capital) 0.08% Small add +0.6% 904,259 $52M History
Samantha Mclemore, Patient Capital Management 0.76% Reduce −9.4% 400,698 $23M History
David Witzke, Avidity Partners Management 0.97%, was 0.81% Add +61.5% 105,000 $6.1M History
Duan Yongping, H&H International Investment 0.01% Hold 20,000 $1.2M History

5 current, options excluded

Weight bar: held both quarters added sold at this quarter’s reported price

Insider trades

Open-market buys and sales by TEM's executives, directors and 10% owners in the last 12 months, from their Form 4s

All TEM insider trades
  • None no insider bought on the open market
  • $284K sold by 1 insider outside a trading plan
  • $200M sold by 10 insiders under 10b5-1 plans
  1. Thomas Edward Schoenherr CEO, Diagnostics
    Planned sale
    $874K 10,281 shares at $85.00 12% of stake
    Traded Sep 25 Filed Sep 29
    ↗
  2. Eric P Lefkofsky CEO
    Planned sale
    $19.4M 250,000 shares at $77.47 71% of stake
    Traded Sep 22 Filed Sep 24
    ↗
  3. Ryan Fukushima CEO, Data
    Planned sale
    $49K 700 shares at $70.00 4.2% of stake
    Traded Sep 16 Filed Sep 18
    ↗
  4. Andrew Polovin EVP, Chief Legal Officer
    Planned sale
    $221K 2,951 shares at $75.00 2.1% of stake
    Traded Sep 17 Filed Sep 18
    ↗
  5. Ryan M Bartolucci Chief Accounting Officer
    Planned sale
    $530K 7,062 shares at $75.00 10% of stake
    Traded Sep 17 Filed Sep 18
    ↗
  6. Eric P Lefkofsky CEO
    Planned sale
    $16.1M 200,000 shares at $80.57 20% of stake
    Traded Sep 17 Filed Sep 18
    ↗
  7. Ryan Fukushima CEO, Data
    Planned sale
    $1.9M 30,846 shares at $62.71 65% of stake
    Traded Sep 1 Filed Sep 3
    ↗
  8. Jennifer A Doudna Director
    Planned sale
    $44K 676 shares at $65.55 2.6% of stake
    Traded Sep 1 Filed Sep 3
    ↗
  9. David R Epstein Director
    Planned sale
    $16K 250 shares at $65.55 0.8% of stake
    Traded Sep 1 Filed Sep 3
    ↗
  10. Nadja West Director
    Planned sale
    $207K 3,000 shares at $69.00 8.6% of stake
    Traded Aug 28 Filed Sep 1
    ↗
  11. Eric P Lefkofsky CEO
    Planned sale
    $828K 11,848 shares at $69.87 7.3% of stake
    Traded Aug 25 Filed Aug 27
    ↗
  12. Eric P Lefkofsky CEO
    Planned sale
    $16.3M 238,152 shares at $68.39 60% of stake
    Traded Aug 25 Filed Aug 27
    ↗
  13. Thomas Edward Schoenherr CEO, Diagnostics
    Planned sale
    $189K 2,694 shares at $70.00 3% of stake
    Traded Aug 21 Filed Aug 25
    ↗
  14. Ryan Fukushima CEO, Data
    Planned sale
    $1M 14,286 shares at $70.00 23% of stake
    Traded Aug 21 Filed Aug 25
    ↗
  15. Thomas Edward Schoenherr CEO, Diagnostics
    Planned sale
    $472K 8,082 shares at $58.40 8.3% of stake
    Traded Aug 19 Filed Aug 20
    ↗

Also filed in the last 12 months, not counted as buying or selling: 30 sales to cover taxes, 20 stock grants, and 6 gifts.

Congress

2 members of Congress traded TEM in the last three years: 3 buys and 0 sales. 2 members listed it in 2025 annual reports.

All Congress trades
  1. Nancy Pelosi D-CA-11Spouse Buy $50K–$100K Jan 16 filed Jan 23
  2. Robert P. Bresnahan, Jr. R-PA-8 Buy $1K–$15K May 9, 2025 filed Jun 9, 2025
  3. Nancy Pelosi D-CA-11Spouse BuyOption $50K–$100K Jan 14, 2025 filed Jan 17, 2025

SEC filings

Recent issuer filings from EDGAR, 6 shown.

Filed Form Detail Links
424B3 Filing Doc
8-K 2.02,7.01,9.01 Filing Doc
10-Q Filing Doc
SCHEDULE 13D/A — Filing Doc
8-K 7.01,9.01 Filing Doc
8-K 1.01,9.01 Filing Doc

Source: SEC EDGAR submissions, updated 1 day ago. All on EDGAR

Financials

US-GAAP annual figures by fiscal year, as tagged in Form 10-K. Each value links to its SEC filing.

Income statement

Metric FY2024 FY2025
Revenue $0.693B $1.27B
Net income -$705.81M -$245.03M
Net margin * -101.8% -19.3%

Balance sheet

Metric FY2024 FY2025
Total current assets $0.668B $1.17B
Total non-current assets * $0.259B $1.11B
Total assets $0.926B $2.27B
Total current liabilities $291.07M $372.39M
Total non-current liabilities * $0.579B $1.41B
Total equity $56.34M $491.33M

Cash flow

Metric FY2024 FY2025
Cash from operations -$189.04M -$218.09M
Cash from investing -$130.39M -$398.36M
Cash from financing $494.33M $884.12M
Net change in cash $175.23M $267.62M

Source: SEC companyfacts (US-GAAP 10-K). A * marks a computed figure, not a single XBRL tag. Fiscal years are as the issuer labels them. Follow The Filings does not adjust or audit these figures.

Ownership over time

13Fs that reported it each quarter. Click a bar for that quarter’s holders.